All A-CHESS users received the HCV intervention content, which includes educational information, private messages tailored to an individuals stage of HCV care, and a public discussion forum. goals of this paper are to describe: (1) the components and functionality of an HCV intervention incorporated into the existing A-CHESS system; and (2) how data are collected and will be used to evaluate HCV testing, linkage to care, and treatment. Methods People with recent opioid use were enrolled in a randomized controlled trial to test whether A-CHESS reduced relapse. We developed and implemented HCV intervention content within the A-CHESS platform to simultaneously evaluate whether A-CHESS improved secondary outcomes related to HCV care. All A-CHESS users received the HCV intervention content, which includes educational information, private messages tailored to an individuals stage of HCV care, and a public discussion forum. Data on patients HCV risk behaviors and stage of care were collected through quarterly telephone interviews and weekly surveys delivered through A-CHESS. The proportion of people with opioid use disorder who are ZINC13466751 HCV untested, HCV-negative, HCV antibody-positive, or HCV RNACpositive, ZINC13466751 as well as linked to care, treated and cured at baseline is described here. The 24-month follow-up is ongoing and will be completed in April 2020. Survey data will then be used to assess whether individuals who ZINC13466751 received the HCV-enhanced A-CHESS intervention were more likely to reduce risky injection behaviors, receive HCV testing, link to medical care, initiate treatment, and be cured of HCV compared to the control group. Results Between April 2016 and April 2018, 416 individuals were enrolled and completed the baseline interview. Of these individuals, 207 were then randomly assigned to the control arm and 209 were assigned to the intervention arm. At baseline, 202 individuals (49%) self-reported ever testing HCV antibody-positive. Of those, 179 (89%) reported receiving HCV RNA confirmatory testing, 134 (66%) tested HCV RNACpositive, 125 (62%) were linked to medical care and 27 (13%) were treated and cured of HCV. Of the remaining 214 individuals who had never tested HCV antibodyCpositive, 129 (31%) had tested HCV antibodyCnegative within the past year and 85 (20%) had not been tested within the past year. Conclusions The A-CHESS mobile health system allows for the implementation of a bundle of services as well as the collection of longitudinal data related to drug use and HCV care among people with opioid DNAJC15 use disorders. This study will provide preliminary evidence to determine whether HCV-specific services embedded into the A-CHESS program can improve HCV outcomes for people engaged in addiction treatment. Trial Registration ClinicalTrials.gov “type”:”clinical-trial”,”attrs”:”text”:”NCT02712034″,”term_id”:”NCT02712034″NCT02712034; https://clinicaltrials.gov/ct2/show/”type”:”clinical-trial”,”attrs”:”text”:”NCT02712034″,”term_id”:”NCT02712034″NCT02712034 International Registered Report Identifier (IRRID) DERR1-10.2196/12620 as an answer choice to HCV questions (See the Multimedia Appendix 1). At the time of the ZINC13466751 baseline assessment, 93% of HCV RNACpositive individuals reported they had seen a medical provider for HCV, a level substantially higher than what had been reported in prior studies [26,53,54]. Because the survey questions did not specifically ask whether participants saw a provider specifically to discuss starting HCV treatment, our research might overestimate true linkage to HCV treatment. Future research should specify information on the scientific encounter that are appealing. Thankfully, the quarterly follow-up research do talk to if people have received any lab tests to determine if they have proof liver organ disease, and these replies allows us to estimation if people received some scientific evaluation to assess their candidacy for HCV treatment after enrollment. Many intrapersonal qualities of a person that aren’t measured through A-CHESS might influence engagement in care. For instance, self-control, company, and self-awareness are areas of conscientiousness thought to impact engagement in health care [55]. Additionally, replies to mobile wellness interventions aren’t likely to end up being uniform over the research population as people differ significantly within their capability and willingness to activate in online conversation, a construct that’s tough to measure. Bottom line.